Adult T-cell leukemia cells overexpress Wnt5a and promote osteoclast differentiation

Blood

Volumn 121, Issue 25, 2013, Pages 5045-5054

  Bellon, Marcia ^a   Ko, Nga Ling ^a   Lee, Min Jung ^b   Yao, Yuan ^a   Waldmann, Thomas A ^b   Trepel, Jane B ^b   Nicot, Christophe ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CYCLIN D1; CYCLOOXYGENASE 2; DISHEVELLED PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; LYMPHOID ENHANCER FACTOR 1; MYC PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN; PROTEIN C JUN; PROTEIN P30; PTHLH PROTEIN; ROR1 PROTEIN; RYK PROTEIN; SURVIVIN; T CELL FACTOR PROTEIN; TAX PROTEIN; TCF4 PROTEIN; TRANSCRIPTION FACTOR 7; TYROSINE KINASE LIKE ORPHAN RECEPTOR 2; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; WNT PROTEIN; WNT10A PROTEIN; WNT3 PROTEIN; WNT3A PROTEIN; WNT5A PROTEIN; WNT8A PROTEIN; WNT9A PROTEIN; ONCOPROTEIN; TRANSCRIPTOME; WNT5A PROTEIN, HUMAN;

ANIMAL CELL; ARTICLE; BONE ATROPHY; CALCIUM SIGNALING; CELL POLARITY; CONTROLLED STUDY; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HYPERCALCEMIA; MOUSE; NONHUMAN; OSTEOCLASTOGENESIS; OSTEOLYSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; T CELL LEUKEMIA; WESTERN BLOTTING; WNT SIGNALING PATHWAY; ANIMAL; BIOSYNTHESIS; CELL DIFFERENTIATION; COCULTURE; CYTOLOGY; FLOW CYTOMETRY; GENETICS; METABOLISM; OSTEOCLAST; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; BLOTTING, WESTERN; CELL DIFFERENTIATION; CELL LINE, TUMOR; COCULTURE TECHNIQUES; FLOW CYTOMETRY; HUMANS; LEUKEMIA-LYMPHOMA, ADULT T-CELL; MICE; OSTEOCLASTS; PROTO-ONCOGENE PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; TRANSCRIPTOME; WNT PROTEINS;

EID: 84882306148     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-07-439109     Document Type: Article

References (42)

1. Zhao C, Blum J, Chen A, et al. Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell. 2007;12(6): 528-541.
2. Guo W, Lasky JL, Chang CJ, et al. Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formation. Nature. 2008; 453(7194):529-533.
3. Simon M, Grandage VL, Linch DC, Khwaja A. Constitutive activation of the Wnt/beta-catenin signalling pathway in acute myeloid leukaemia. Oncogene. 2005;24(14):2410-2420.
4. Lu D, Zhao Y, Tawatao R, et al. Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 2004;101(9): 3118-3123.
5. Gelebart P, Anand M, Armanious H, et al. Constitutive activation of the Wnt canonical pathway in mantle cell lymphoma. Blood. 2008; 112(13):5171-5179.
6. Valencia A, Román-Gómez J, Cervera J, et al. Wnt signaling pathway is epigenetically regulated by methylation of Wnt antagonists in acute myeloid leukemia. Leukemia. 2009;23(9): 1658-1666.
7. Chim CS, Pang R, Fung TK, Choi CL, Liang R. Epigenetic dysregulation of Wnt signaling pathway in multiple myeloma. Leukemia. 2007; 21(12):2527-2536.
8. Roman-Gomez J, Jimenez-Velasco A, Cordeu L, et al. WNT5A, a putative tumour suppressor of lymphoid malignancies, is inactivated by aberrant methylation in acute lymphoblastic leukaemia. Eur J Cancer. 2007;43(18):2736-2746.
9. Camilli TC, Weeraratna AT. Striking the target in Wnt-y conditions: intervening in Wnt signaling during cancer progression. Biochem Pharmacol. 2010;80(5):702-711.
10. Long F. Building strong bones: molecular regulation of the osteoblast lineage. Nat Rev Mol Cell Biol. 2012;13(1):27-38.
11. Maeda K, Kobayashi Y, Udagawa N, et al. Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis. Nat Med. 2012;18(3): 405-412.
12. Datta A, Sinha-Datta U, Dhillon NK, Buch S, Nicot C. The HTLV-I p30 interferes with TLR4 signaling and modulates the release of pro- and anti-inflammatory cytokines from human macrophages. J Biol Chem. 2006;281(33): 23414-23424.
13. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 1995;378(6559):785-789.
14. Okada Y, Tsukada J, Nakano K, Tonai S, Mine S, Tanaka Y. Macrophage inflammatory protein-1alpha induces hypercalcemia in adult T-cell leukemia. J Bone Miner Res. 2004;19(7): 1105-1111.
15. Nosaka K, Miyamoto T, Sakai T, Mitsuya H, Suda T, Matsuoka M. Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor kappaB ligand on adult T-cell leukemia cells. Blood. 2002;99(2):634-640.
16. Cawthorn WP, Bree AJ, Yao Y, et al. Wnt6, Wnt10a and Wnt10b inhibit adipogenesis and stimulate osteoblastogenesis through a b-catenin-dependent mechanism. Bone. 2012;50(2): 477-489.
17. Kikuchi A, Yamamoto H, Sato A, Matsumoto S. Wnt5a: its signalling, functions and implication in diseases. Acta Physiol (Oxf). 2012;204(1):17-33.
18. Ho HY, Susman MW, Bikoff JB, et al. Wnt5a-Ror-Dishevelled signaling constitutes a core developmental pathway that controls tissue morphogenesis. Proc Natl Acad Sci USA. 2012; 109(11):4044-4051.
19. Jeong SJ, Pise-Masison CA, Radonovich MF, Park HU, Brady JN. Activated AKT regulates NF-kappaB activation, p53 inhibition and cell survival in HTLV-1-transformed cells. Oncogene. 2005; 24(44):6719-6728.
20. Bellon M, Nicot C. Central role of PI3K in transcriptional activation of hTERT in HTLV-I-infected cells. Blood. 2008;112(7):2946-2955.
21. Kiyokawa T, Yamaguchi K, Takeya M, et al. Hypercalcemia and osteoclast proliferation in adult T-cell leukemia. Cancer. 1987;59(6): 1187-1191.
22. Richard V, Lairmore MD, Green PL, et al. Humoral hypercalcemia of malignancy: severe combined immunodeficient/beige mouse model of adult T-cell lymphoma independent of human T-cell lymphotropic virus type-1 tax expression. Am J Pathol. 2001;158(6):2219-2228.
23. Katagiri T, Akiyama S, Namiki M, et al. Bone morphogenetic protein-2 inhibits terminal differentiation of myogenic cells by suppressing the transcriptional activity of MyoD and myogenin. Exp Cell Res. 1997;230(2):342-351.
24. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology. 2001;142(12):5050-5055.
25. Kieslinger M, Folberth S, Dobreva G, et al. EBF2 regulates osteoblast-dependent differentiation of osteoclasts. Dev Cell. 2005;9(6):757-767.
26. Tsukasaki K, Hermine O, Bazarbachi A, et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol. 2009;27(3): 453-459.
27. Fujihira T, Eto S, Sato K, et al. Evidence of bone resorption-stimulating factor in adult T-cell leukemia. Jpn J Clin Oncol. 1985;15(2):385-391.
28. Takaori-Kondo A, Imada K, Yamamoto I, et al. Parathyroid hormone-related protein-induced hypercalcemia in SCID mice engrafted with adult T-cell leukemia cells. Blood. 1998;91(12): 4747-4751.
29. Hino M, Yamane T, Ohta K, et al. Bone resorption associated with uncoupling of osteoclastic and osteoblastic activities in adult T cell leukemia with hypercalcemia: case report. Ann Hematol. 2001; 80(7):426-429.
30. Chung EJ, Hwang SG, Nguyen P, et al. Regulation of leukemic cell adhesion, proliferation, and survival by beta-catenin. Blood. 2002;100(3):982-990.
31. Kim K, Pang KM, Evans M, Hay ED. Overexpression of beta-catenin induces apoptosis independent of its transactivation function with LEF-1 or the involvement of major G1 cell cycle regulators. Mol Biol Cell. 2000; 11(10):3509-3523.
32. Jesse S, Koenig A, Ellenrieder V, Menke A. Lef-1 isoforms regulate different target genes and reduce cellular adhesion. Int J Cancer. 2010; 126(5):1109-1120.
33. Skokowa J, Cario G, Uenalan M, et al. LEF-1 is crucial for neutrophil granulocytopoiesis and its expression is severely reduced in congenital neutropenia. Nat Med. 2006;12(10):1191-1197.
34. He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science. 1998;281(5382):1509-1512.
35. Pise-Masison CA, Radonovich M, Dohoney K, et al. Gene expression profiling of ATL patients: compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability. Blood. 2009;113(17): 4016-4026.
36. Chien AJ, Moore EC, Lonsdorf AS, et al. Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model. Proc Natl Acad Sci USA. 2009;106(4):1193-1198.
37. McDonald SL, Silver A. The opposing roles of Wnt-5a in cancer. Br J Cancer. 2009;101(2): 209-214.
38. Mikels AJ, Nusse R. Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context. PLoS Biol. 2006; 4(4):e115.
39. Veeck J, Dahl E. Targeting the Wnt pathway in cancer: the emerging role of Dickkopf-3. Biochim Biophys Acta. 2012;1825(1):18-28.
40. Ma G, Yasunaga J, Fan J, Yanagawa S, Matsuoka M. HTLV-1 bZIP factor dysregulates the Wnt pathways to support proliferation and migration of adult T-cell leukemia cells. Oncogene. 2012. [Epub ahead of print]
41. Martín V, Valencia A, Agirre X, et al. Epigenetic regulation of the non-canonical Wnt pathway in acute myeloid leukemia. Cancer Sci. 2010;101(2): 425-432.
42. Hanaki H, Yamamoto H, Sakane H, et al. An anti-Wnt5a antibody suppresses metastasis of gastric cancer cells in vivo by inhibiting receptor-mediated endocytosis. Mol Cancer Ther. 2012; 11(2):298-307.